Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Remix Therapeutics
AddedFeb 13, 2024
UpdatedJun 18, 2026
Remix Therapeutics

Remix Therapeutics

Series D

Remix Therapeutics: A biotech firm innovating small molecule therapies to revolutionize disease treatment.

HQ
Watertown, MA, US
Founded
2018
Overview
Compare
Fundraising
Employees

Remix Therapeutics is a biotechnology company focused on developing novel small molecule therapies to reprogram RNA processing, aiming to treat diseases in entirely new ways. Their mission is to revolutionize disease treatment through innovative approaches to RNA biology, targeting a broad range of medical conditions.

The company has made significant strides in the biotech industry, leveraging cutting-edge research to create impactful therapies. Their work has garnered attention for its potential to transform medical treatment paradigms, positioning Remix Therapeutics as a leader in RNA-focused drug development.

Remix Therapeutics - Similar Companies

Nextrna Therapeutics logo

Nextrna Therapeutics

ReviR Therapeutics logo

ReviR Therapeutics

revirtx.com

Arrakis Therapeutics logo

Arrakis Therapeutics

arrakistx.com

ReNAgade Therapeutics logo

ReNAgade Therapeutics

858 Therapeutics logo

858 Therapeutics

8five8tx.com

Remedium Bio logo

Remedium Bio

remedium-bio.com

Cedilla Therapeutics logo

Cedilla Therapeutics

Rekindle Therapeutics logo

Rekindle Therapeutics

Orbital Therapeutics logo

Orbital Therapeutics

Rnaderm Therapeutics logo

Rnaderm Therapeutics

Faze Medicines logo

Faze Medicines

fazemed.com

Rgenta Therapeutics logo

Rgenta Therapeutics

rgentatx.com

Alltrna logo

Alltrna

alltrna.com

CAMP4 Therapeutics logo

CAMP4 Therapeutics

camp4tx.com

Renibus Therapeutics logo

Renibus Therapeutics

Remix Therapeutics - Quick Facts

Who are Remix Therapeutics' competitors?

Companies similar to Remix Therapeutics include Nextrna Therapeutics, ReviR Therapeutics, Arrakis Therapeutics and ReNAgade Therapeutics.

When was Remix Therapeutics founded?

Remix Therapeutics was founded in 2018.

Where is Remix Therapeutics' headquarters located?

Remix Therapeutics' headquarters is located in Watertown, MA, US.

When was Remix Therapeutics' last funding round?

Remix Therapeutics' most recent funding round was for $60M (USD) in January 2024.

How much has Remix Therapeutics raised to-date?

As of Jan 3, 2024, Remix Therapeutics has raised a total of $211M (USD).

How many employees does Remix Therapeutics have?

Remix Therapeutics has 71 employees as of Feb 5, 2024.

Remix Therapeutics - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Therapies
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 4 more industry codes
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified